AGE inhibition at pathology initiation
PrimaryPraetego's core causal theory is that advanced glycation end-products (AGEs) help initiate pathology in chronic diseases of aging, and that small-molecule AGE inhibitors can deter AGE formation early enough to slow or prevent downstream disease processes. The company links AGE-driven pathology to oxidative stress and positions this mechanism as relevant across neurodegeneration, Alzheimer's disease, diabetic microvascular disease, and cardiovascular disease. A testable prediction is that Praetego's Amadorin/AGE-inhibiting candidates should reduce AGE formation or AGE-associated biomarkers before advanced tissue damage occurs, with downstream improvements in disease models driven by oxidative stress or glycation pathology.
Popperian evaluation
The core premise is biologically credible: AGEs are plausibly involved in aging-related pathology and are mechanistically linked to oxidative stress, diabetic complications, vascular injury, and neurodegenerative processes. However, the theory makes a stronger causal claim that AGEs help initiate pathology across multiple chronic diseases, which is less firmly supported by the provided evidence. The dossier context supports relevance and mechanistic plausibility, but provides no direct publication evidence here showing that AGE formation is an initiating driver rather than a downstream marker or amplifier.
Supporting evidence: The reasoning graph states that AGE-driven pathology is linked to oxidative stress.; The theory includes a mechanistic intervention point: inhibiting AGE formation before advanced tissue damage occurs.; Praetego positions AGE inhibition across neurodegeneration, Alzheimer's disease, diabetic microvascular disease, and cardiovascular disease.; A cited dossier excerpt identifies pyridoxamine as an AGE inhibitor in a clinical context.
Counter evidence: The evidence context includes no supporting publication IDs for the central premise.; The provided material does not establish that AGEs initiate pathology rather than correlate with or worsen existing pathology.; The broad disease scope increases the burden of proof because AGE causality may differ across Alzheimer's disease, diabetes, cardiovascular disease, and other aging disorders.
The theory offers a coherent explanation for a subset of disease biology in which glycation, oxidative stress, and tissue damage interact. It could explain why early AGE suppression might improve models driven by glycation or oxidative injury. But the provided evidence does not show that this account explains observed disease outcomes better than competing mechanisms such as amyloid/tau pathology, insulin resistance, inflammation, vascular dysfunction, mitochondrial dysfunction, or general oxidative stress independent of AGEs.
Supporting evidence: The theory links AGE formation to oxidative stress and downstream disease processes.; The prediction connects biomarker reduction to functional improvement in disease models driven by oxidative stress or glycation pathology.; The mechanism is potentially cross-cutting, which could explain pathology across several aging-associated diseases.
Counter evidence: No direct comparative evidence is provided showing AGE inhibition outperforms alternative mechanistic explanations.; The disease areas named have multiple well-supported causal pathways, making AGE initiation only one possible explanation.; The evidence context contains positioning and leadership evidence, but little disease-outcome evidence.
The theory is substantially falsifiable because it makes concrete, temporally ordered predictions: Praetego's candidates should reduce AGE formation or AGE-associated biomarkers before advanced tissue damage, and those reductions should translate into downstream benefits in relevant disease models. It could be challenged by showing adequate tissue exposure without biomarker reduction, biomarker reduction without disease-model improvement, or benefits occurring independently of AGE modulation. The main limitation is that the breadth of indications could allow post hoc narrowing unless disease-specific thresholds and models are prespecified.
Supporting evidence: The stated prediction requires reduced AGE formation or AGE-associated biomarkers before advanced tissue damage occurs.; The theory predicts downstream improvements in disease models driven by oxidative stress or glycation pathology.; The assumptions about early AGE timing and tissue-relevant inhibition are experimentally testable.
Counter evidence: The theory spans multiple diseases, which could weaken falsifiability if failed indications are dismissed as non-AGE-driven cases after the fact.; The provided evidence does not specify exact biomarkers, effect sizes, tissue compartments, time windows, or disease-model endpoints.; Downstream disease improvement may be confounded by off-target antioxidant or metabolic effects.
Reasoning tree
Public endorsements
In a 2021 Praetego presentation by Pepper Landson, the company is described as developing AGE inhibitors that 'deter AGE formation at the initiation of pathology' and as targeting aging-related diseases driven by oxidative stress, which directly matches the stated theory.
Evidence publication IDs: e51f35ac-bdc2-4f93-8649-328c7264032a
Khalifah is publicly identified as Praetego's CSO, co-authored work on the Maillard reaction and aging, and is listed on an abstract describing pyridoxamine as an AGE inhibitor in a clinical context. Taken together, that is public support for the AGE-inhibition mechanism rather than mere silence or contradiction.